U.S. inspectors have found new breakdowns at a Sun Pharmaceuticals plant in India that produces medications for U.S. customers, ProPublica reported July 16. The FDA found the factory failed to ...

The latest inspection comes 2 1/2 years after the agency allowed Sun Pharma to keep shipping some drugs to Americans even after banning the factory from the U.S. market because of quality problems.

From my colleague Drew Joseph: Ahead of an advisory committee meeting Thursday focused on GSK’s multiple myeloma drug Blenrep, the FDA pointed to concerns about the high rates of eye issues that have ...

Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently ...

A Sun Pharmaceutical plant in India that has been repeatedly cited by the FDA for serious quality control issues failed ...

Shares of HDFC Life Insurance, HDB Financial, ICICI Lombard, Just Dial will remain in focus as companies will declare Q1 ...

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

India's equity indices ended a four-session decline, as inflation data came in lower than anticipated, increasing hopes for ...

Markets ended higher on Monday, snapping a four-day losing streak. Nifty reclaimed 25,200, led by autos and pharma, while ...

India's equity benchmarks snapped a four-session losing streak on Tuesday, as lower-than-expected domestic inflation data boosted expectations of further rate cuts this year by the central bank. The ...

Indian benchmark indices concluded the trading session on a positive note, with the Sensex gaining over 300 points to end at 83,570. Nifty closed near the 25,200 mark at 25,195.

Indian drugmaker Sun Pharmaceutical Industries together with its subsidiaries announced that further to its intimation dated ...